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This study examined the eﬀects of lithium on gene expression and activity of the antioxidant enzymes copper zinc superoxide
dismutase (SOD1), manganese superoxide dismutase (SOD2), catalase (CAT), glutathione peroxidase (GPx), and glutathione
reductase (GR) in the hippocampus of chronically stressed rats. In addition, we examined the eﬀects of lithium on anxiety
behaviors, hippocampal concentrations of dopamine (DA) and malondialdehyde (MDA), protein levels of brain-derived
neurotrophic factor (BDNF), tyrosine hydroxylase (TH), dopamine transporter (DAT), and catechol-O-methyltransferase
(COMT), as well as activity of monoamine oxidase (MAO) in chronically stressed rats. The investigated parameters were
quantiﬁed by real-time RT-PCR, Western blot analyses, and assays of enzyme activities. We found that lithium did not change
gene expression of SOD1, CAT, GPx, and GR but decreased gene expression of SOD2 in chronically stressed rats. A very
important result in this study was that lithium treatment decreased the enzyme activities of SOD1 and SOD2 but increased the
enzyme activities of GPx and GR in stress condition, which indicates the control of redox balance. The reduced concentration of
MDA conﬁrms this. In addition, we found that lithium treatment decreased high protein levels of BDNF and DAT in
chronically stressed rats to the level found in unstressed animals. Also, lithium treatment increased the expression of TH but
decreased the enzyme activity of MAO B, which contributed to the increase of hippocampal concentration of DA in chronically
stressed rats to the level of unstressed animals. Finally, lithium treatment in animals exposed to chronic stress increased the time
spent in open arms. Lithium-induced modulation of hippocampal antioxidant status and attenuation of oxidative stress
stabilized behavior in animals with high anxiety index. In addition, reduced oxidative stress was followed by the changes of both
turnover of DA and levels of BDNF protein in chronically stressed rats treated with lithium. These ﬁndings may be important in
preclinical research of the eﬀects of lithium on oxidative stress level in pathological conditions.
1. Introduction
Molecular interactions in the neuroendocrine system under
stress condition can lead to homeostatic disorders [1, 2].
Chronic stress induces overactivation and dysfunction of
stress-activated systems, resulting in further brain damage
and mood disorders [3, 4]. One of the key mechanisms for
the modulation of brain functions in stress conditions is
monoaminergic signaling. In addition, it is known that
brain-derived neurotrophic factor (BDNF) modulates the
activity of monoaminergic systems in the rat brain [5]. Nor-
mal monoaminergic turnover results from balance among
synthesis, degradation, release, and reuptake of monoamines.
In our previous studies, we found that chronic restraint stress
(CRS) induced signiﬁcant decrease of both hippocampal
dopamine (DA) concentration [6] and protein levels of tyro-
sine hydroxylase (TH), a “rate-limiting” enzyme of dopamine
biosynthesis [7], which conﬁrmed that the hippocampus was
particularly sensitive to chronic stress [8, 9]. Data about the
dynamics of DA transmission and degradation are very
important for understanding dopaminergic turnover. The
dynamics of DA transmission is regulated by reuptake
through dopamine transporter (DAT). Monoamine oxidase
(MAO) and catechol-O-methyltransferase (COMT) are
enzymes which catalyze the oxidative deamination of mono-
amine neurotransmitters including DA. The byproducts of
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these reactions include a number of potentially neurotoxic
species, such as hydrogen peroxide and ammonia. Hydrogen
peroxide can trigger the production of reactive oxygen species
(ROS) and induce mitochondrial damage and neuronal apo-
ptosis. It is known that the brain is particularly vulnerable to
oxidative damage since it contains large amounts of polyun-
saturated fatty acids and possesses low antioxidant capacity
[10, 11]. Malondialdehyde (MDA) is the frequently used bio-
marker of oxidative stress in many health problems including
mood disorders. The literature data have shown that there is a
direct involvement of oxidative stress in anxiety-like behavior
in rodents [12]. Our earlier research conﬁrmed that chronic
restraint stress (CRS) inﬂuenced anxiety-like behavior in rats
[6]. In the pathophysiology of mood disorders, lithium is
known as an eﬀective drug in the long-term stabilization of
moods. Also, lithium has a neurotrophic and neuroprotective
function and improves total antioxidant activity [13–16]. In
our earlier studies, we found that CRS induced increased
activity of superoxide dismutase 1 (SOD1), superoxide dis-
mutase 2 (SOD2), and catalase (CAT) in the hippocampus
[17]. The increased activity of antioxidant enzymes may be
an important adaptive phenomenon of the antioxidant
defense system in chronically stressed rats [17]. It is known
that treatment with antidepressants signiﬁcantly decreased
the activities of SOD and CAT in depressive patients [18], as
well as increasedDA levels in the prefrontal cortex [19]. How-
ever, very little is known about the antioxidant defense system
and turnover ofDA in animals with high anxiety index treated
with lithium.
Because of the direct involvement of oxidative stress in
anxiety-like behavior in stress conditions, detecting the
changes of gene expression and activity of the antioxidant
enzymes as well as monitoring the changes of dopaminergic
turnover in the hippocampus in chronically stressed rats
treated with lithium may be very important in the research
on the role of lithium in maintaining antioxidant status in
pathological conditions. Therefore, in this study we exam-
ined gene expression and activity of the antioxidant enzymes
SOD, CAT, glutathione peroxidase (GPx), and glutathione
reductase (GR), as well as protein levels of BDNF, TH,
DAT, and COMT and activity of MAO and concentrations
of DA and MDA in the hippocampus of chronically stressed
rats treated with lithium. An additional aim of the study was
to test anxiety in chronically stressed rats treated with lithium.
2. Materials and Methods
2.1. Animals and Stress Models. Eleven-week-oldWistar male
rats (300-340 g) were maintained under standard laboratory
conditions with water and food ad libitum and kept three
to four per cage [20]. The care was taken to minimize the
pain and discomfort of the animals according to the recom-
mendations of the Ethical Committee of the Vinča Institute
of Nuclear Sciences, Belgrade, Serbia, which follows the
guidelines of the registered “Serbian Society for the Use of
Animals in Research and Education.” In accordance with
our previous protocol [21], animals were divided into three
groups: CRS group (n = 20) consisted of animals exposed to
chronic restraint stress treatment and CRS+Li group (n = 20)
consisted of animals exposed to chronic restraint stress treat-
ment with Li given each day immediately prior to daily
restraint. Restraint stress was performed by placing each ani-
mal in a 25 × 7 cm plastic bottle as described previously [22].
The animals in these groups were exposed to 2 h of restraint
stress every day at random times during the light period of
the light/dark cycle to avoid habituation during the experi-
mental procedure of 14 days [23]. Lithium was administered
intraperitoneally to the animals, once a day for 14 days as
described previously [24]. The initial lithium dose was
1.5mEq/kg for 2 days and was then increased to 2.3mEq/kg
for 7 days, followed by 3mEq/kg for 5 days. This lithium
administration protocol maintained the plasma lithium con-
centration above the minimal therapeutic concentration
(i.e., 0.4mM) for the treatment of bipolar disorder throughout
the treatment period. Anxiety-like behaviors were assessed by
elevated plus maze (EPM) test. Ten animals from each group
were tested on the EPM. Animals which were used to test the
behavior were not used for further analysis. In order to exam-
ine whether lithium decreased high protein levels of BDNF
and DAT in chronically stressed rats to the level of unstressed
animals, we introduced Control group. The Control group
(n = 10) was not exposed to any treatment. To reduce variance
in the physiological parameters due to daily rhythms, the
remaining animals (n = 10 from each group) were sacriﬁced
at the same time point in the circadian cycle, between 9:00
and 11:00 am, i.e., one day after the last treatments. Animals
were sacriﬁced under no-stress conditions by rapid decapita-
tion. The hippocampuses were rapidly dissected, frozen in
liquid nitrogen, and stored at −70°C until analyzed.
2.2. Dopamine Measurement. Hippocampus tissues were
homogenized in 0.01N HCl in the presence of EDTA and
sodium metabisulﬁte. Dopamine concentration in hippo-
campus fractions was determined using 3-CAT Research
ELISA kits (Labor Diagnostika Nord, Nordhorn, Germany)
according to the manufacturer’s protocol. Absorbance was
determined at 450nm using a microplate reader (Stat Fax
2100). Concentrations were normalized to 1 g of tissues in
homogenate. Values were expressed as ng of DA per g of tis-
sues which is in accordance with our previous protocol [25].
2.3. Monoamine Oxidase Enzyme Activities. The determina-
tion of MAO B activity was performed using the Amplex
Red Monoamine Oxidase Assay (A12214, Molecular
Probes, USA), described by Zhou and Panchuk-Voloshina
[26]. This assay is based on the detection of H2O2 in a
horseradish peroxidase-coupled reaction using N-acetyl-3,
7-dihydroxyphenoxazine (Amplex Red), a highly sensitive
and stable probe for H2O2. Fluorescence was measured with
a ﬂuorometer using excitation at 560 ± 10 nm and ﬂuores-
cence detection at 590 ± 10 nm. Monoamine oxidase activity
was expressed as U/mg of protein as previously described by
Gavrilović et al. [25].
2.4. RNA Isolation, cDNA Synthesis, and Real-Time RT-PCR.
Methods of RNA isolation and cDNA synthesis were
described previously by Gavrilović et al. [27]. Total RNAs
were isolated from the hippocampal tissue by using TRIZOL
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reagent (Invitrogen, USA). Reverse transcription was per-
formed using Ready-To-Go You-Prime First-Strand Bead
(Amersham Biosciences, UK) and pd (N)6 RandomHexamer
(Amersham Biosciences, UK) primer according to the manu-
facturer’s protocol, which is in accordance with the protocol
of Gavrilović et al. [28]. CuZn SOD (SOD1), Mn SOD
(SOD2), CAT, GPx, and GR mRNA levels were quantiﬁed
by quantitative real-time RT-PCR, as described previously
by Gavrilović et al. [27]. TaqMan PCR assays were carried
out using Assay-on-Demand Gene Expression Products
(Applied Biosystems, USA) for SOD1 (Rn00566938_m1),
SOD2 (Rn00690587_g1), CAT (Rn00560930_m1), GPx
(Rn00577994_g1), and GR (Rn01482159_m1). The reference
gene (endogenous control) was included in each analysis to
correct for the diﬀerences in the interassay ampliﬁcation eﬃ-
ciency and all transcripts were normalized to cyclophilin A
(Rn00690933_m1) expression [28]. Quantiﬁcation was done
using the 2−ΔΔCt method according to Livak and Schmittgen
[29]. The relative expression of the target gene was normal-
ized to cyclophilin A and expressed in relation to the calibra-
tor, i.e., the control sample as previously described by
Gavrilović et al. [28].
2.5. Hippocampal Tissue Homogenization, Measurement of
the Protein Concentration, and Western Blot Analysis. The
hippocampus was homogenized in 0.05M sodium phosphate
buﬀer (pH 6.65). Subsequently, the protein concentration
was determined using BCA method (Thermo Scientiﬁc
Pierce, USA), described by Stich [30]. CuZn SOD (SOD1),
Mn SOD (SOD2), CAT, GPx, GR, BDNF, TH, DAT, and
COMT proteins were assayed by Western blot analysis as
described previously by Gavrilović et al. [27]. Antibodies
used for the quantiﬁcation of speciﬁc proteins were as fol-
lows: SOD1 (SOD-101, Stressgen, USA), SOD2 (SOD-110,
Stressgen, USA), CAT (Calbiochem, Germany), GPx
(sc-30147 Santa Cruz Biotechnology, USA), GR (sc-32886,
Santa Cruz Biotechnology, USA), BDNF (ab6201, Abcam,
USA), TH (ab51191, Abcam, USA), DAT (ab18548, Abcam,
USA), and β-actin (ab8227, Abcam, USA). After washing,
the membranes were incubated in the secondary anti-rabbit
(dilution 1 : 5000, Amersham ECL™Western Blotting Analy-
sis System, UK) antibodies conjugated to horseradish perox-
idase. A secondary antibody was then visualized by the
Western blotting-enhanced chemiluminescent detection sys-
tem (ECL, Amersham Biosciences, UK). The membranes
were exposed to ECL ﬁlm (Amersham Biosciences, UK).
The result was expressed in arbitrary units normalized in
relation to β-actin, which is in accordance with our previous
protocol [27].
2.6. Antioxidant Enzyme Activities. SOD, GPx, and GR
activities were determined using assays for enzyme activities,
as we previously described [31].
2.6.1. Assay of SOD Activity. Total SOD activity was
measured using the Oxis Bioxytech® SOD-525™ Assay (Oxis
International Inc., Portland, OR, USA). The method is based
on the SOD-mediated increase in the rate of autoxidation of
reagent 1 (5,6,6a,11b-tetrahydro-3,9,10-trihydroxybenzo[c]
ﬂuorene, R1) in aqueous alkaline solution, yielding a chro-
mophore with maximum absorbance at 525nm. The kinetic
measurement of the change in absorbance at 525nm was
performed. One SOD-525 activity unit was deﬁned as the
activity that doubles the autoxidation rate of the control
blank. CuZnSOD activity was measured as described above,
after pretreating samples with ethanol-chloroform reagent
(5/3 vol/vol), which inactivates MnSOD. MnSOD activity
was then calculated by subtracting CuZnSOD activity from
total SOD activity [17].
2.6.2. Assay of CAT Activity. CAT activity was determined by
the method of Beutler [32]. The reaction is based on the rate
of H2O2 degradation by catalase contained in the examined
samples. The reaction was performed in an incubation mix-
ture containing 1M Tris-HCl, 5mM EDTA, pH 8.0 and
monitored spectrophotometrically at 230nm. One unit of
CAT activity was deﬁned as 1μmol of H2O2 decomposed
per minute under the assay conditions [21].
2.6.3. Assay of GPx Activity. GPx activity was assessed using
the Oxis Bioxytech GPx-340 Assay (Oxis International Inc.,
Portland, OR, USA), based on the principle that oxidized glu-
tathione (GSSG) produced upon reduction of an organic per-
oxide by GPx is immediately recycled to its reduced form
(GSH) with concomitant oxidation of NADPH to NADP+.
The oxidation of NADPH was monitored spectrophotomet-
rically as a decrease in absorbance at 340nm. One GPx-340
unit was deﬁned as 1μmol of NADH oxidized per minute
under the assay conditions [21].
2.6.4. Assay of GR Activity. Activity of GR was measured
using the Oxis Bioxytech GR-340 Assay (Oxis International
Inc., Portland, OR, USA). The assay is based on the oxidation
of NADPH to NADP+ during the reduction of oxidized glu-
tathione (GSSG), catalyzed by a limiting concentration of
glutathione reductase. The oxidation of NADPH was moni-
tored spectrophotometrically as a decrease in absorbance at
340 nm. One GR-340 unit was deﬁned as 1μmol of NADH
oxidized per minute under the assay conditions [21].
2.7. Malondialdehyde Measurement. Malondialdehyde con-
centration in the hippocampus fractions was determined
using Spectrophotometric Assay for Malondialdehyde Bioxy-
tech® MDA-586 (OXIS Health Products Inc., USA) accord-
ing to the manufacturer’s protocol. The MDA-586 method
is based on the reaction of a chromogenic reagent,
N-methyl-2-phenylindole, with MDA at 45°C. Malondialde-
hyde concentration was expressed as μM/mg of protein,
which is in accordance with our previous protocol [25].
2.8. Elevated Plus Maze (EPM). The EPM consisted of four
elevated (50 cm) contralateral arms (50 cm long and 10 cm
wide) with two opposing arms containing 40 cm high opaque
walls, which is in accordance with our previous protocol [6].
On the day of EPM testing, rats were transported into the
testing room one cage at a time and testing alternated
between CRS animals and CRS+Li animals. Each rat was
placed in a closed arm, facing the center platform and
cage-mates started in the same closed arm, which was
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counterbalanced across trials. Each rat was given 5min to
explore the EPM and then returned to its home cage. The
EPM was cleaned thoroughly using Naturally Living Pet
Odor Eliminator between each rat. EPM performance was
recorded using an overhead video camera for later quantiﬁ-
cation. Open and closed arm entries were deﬁned as the front
two paws entering the arm, and open arm time began the
moment the front two paws entered the open arm and ended
upon exit. Rats that displayed thigmotaxis and an aversion to
the open arms were considered highly anxious [33]. An
added measure of anxiety was calculated for the EPM using
the following equation, which uniﬁes all EPM parameters
into one uniﬁed ratio; anxiety index values range from 0 to
1, with a higher value indicating increased anxiety [34–37].
Anxiety index
= 1 − open arm time/5 min + open arm entry/total entry2
1
2.9. Data Analysis. The data are presented asmeans ± S E M
Diﬀerences of gene expression (mRNA and protein levels) of
SOD1, SOD2, CAT, GPx, GR, BDNF, TH, and DAT; activity
of enzymes (MAO B, SOD1, SOD2, CAT, GPx, and GR); and
concentration of DA and MDA as well as animal behavior
between CRS and CRS+Li animals were analyzed by t-test.
Statistical signiﬁcance was accepted at p < 0 05.
3. Results
3.1. Changes of Levels of TH Protein, DA Concentrations,
BDNF Protein, DAT Protein, COMT Protein, and MAO B
Activity in the Hippocampus. We found that lithium treat-
ment in animals exposed to CRS signiﬁcantly increased levels
of TH protein by 26% (p < 0 001, t-test, Figure 1(a)) and
increased the concentration of DA by 125% (p < 0 001,
t-test, Figure 1(b)) compared with CRS animals. In addition,
lithium treatment decreased levels of BDNF protein by 10%
(p < 0 05, t-test, Figure 2(a)) and decreased levels of DAT
protein by 20% (p < 0 01, t-test, Figure 2(b)) to the level of
unstressed animals. Also, the animals exposed to CRS treated
with lithium showed decreased levels of MAO B activity by
43% (p < 0 001, t-test, Figure 3(a)), while levels of COMT
protein remained unchanged (Figure 3(b)) compared with
CRS animals.
3.2. Changes of MDA Concentrations in the Hippocampus.
Lithium treatment decreased MDA concentrations by 35%
(p < 0 01, t-test, Figure 4) compared with CRS animals.
3.3. Changes of SOD1 mRNA Levels, Protein Levels, and
Enzyme Activity in the Hippocampus. Lithium treatment in
animals exposed to CRS signiﬁcantly decreased the enzyme
activity of SOD1 by 25% (p < 0 01, t-test, Figure 5(a)), while
levels of mRNA and protein (Figure 6(a)) remained
unchanged compared with CRS animals.
3.4. Changes of SOD2 mRNA Levels, Protein Levels, and
Enzyme Activity in the Hippocampus. The animals exposed
to CRS treated with lithium showed decreased levels of
SOD2 mRNA by 16% (p < 0 05, t-test, Figure 6(b)) and pro-
tein by 14% (p < 0 05, t-test, Figure 6(b)) and the enzyme
activity by 37% (p < 0 001, t-test, Figure 5(b)) compared with
CRS animals.
3.5. Changes of CAT mRNA Levels, Protein Levels, and
Enzyme Activity in the Hippocampus. Lithium treatment
did not change signiﬁcantly gene expression and enzyme
activity of CAT in animals exposed to CRS (Figures 5(c)
and 6(c)).
The animals exposed to CRS treated with lithium showed
a decreased ratio of SOD1/CAT and SOD2/CAT compared
with CRS animals.
3.6. Changes of GPxmRNA Levels, Protein Levels, and Enzyme
Activity in the Hippocampus. We found that lithium treat-
ment in animals exposed to CRS signiﬁcantly increased the
enzyme activity of GPx by 23% (p < 0 05, t-test, Figure 5(d)),
while levels of GPx mRNA and protein (Figure 6(d))
remained unchanged compared with CRS animals.
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Figure 1: Eﬀects of lithium on tyrosine hydroxylase (TH) protein levels (a) and concentration of dopamine (DA) (b) in the hippocampus of
animals exposed to CRS. The values are means ± S E M of 10 rats. Statistical signiﬁcance: ∗∗∗p < 0 001 animals exposed to CRS+Li vs. CRS
animals (t-test). The level of TH protein was expressed in arbitrary units normalized in relation to β-actin, and the concentration of DA was
expressed as ng per gram of tissue (ng/g).
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3.7. Changes of GR mRNA Levels, Protein Levels, and Enzyme
Activity in the Hippocampus. Lithium treatment did not
change the gene expression of GR enzymes (Figure 6(e)), but
it signiﬁcantly increased the enzyme activity of GR by 27%
(p < 0 001, t-test, Figure 5(e)) in animals exposed to CRS.
3.8. Changes in Animal Behavior. The animals exposed to
CRS treated with lithium showed signiﬁcant increase of time
spent in open arms compared to CRS rats. Based on these
results, we calculated anxiety index (AI). Lithium treatment
in animals exposed to CRS signiﬁcantly decreased AI by
45% (p < 0 001, t-test, Figure 7), compared with CRS animals.
4. Discussion
The results of this study show that mood stabilizer lithium
modulates hippocampal levels of BDNF, turnover of DA,
and antioxidant defense system and stabilizes behavior in
chronically stressed rats. We observed that CRS increased
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Figure 2: Eﬀects of lithium on brain-derived neurotrophic factor (BDNF) (a) and dopamine transporter (DAT) (b) protein levels in the
hippocampus of animals exposed to CRS. The values are means ± S E M of 10 rats. Statistical signiﬁcance: ∗p < 0 05, ∗∗p < 0 01 animals
exposed to CRS+Li vs. CRS animals (t-test); +p < 0 05 CRS animals vs. Control animals (t-test). The result was expressed in arbitrary units
normalized in relation to β-actin.
CRS CRS + Li
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
M
AO
 B
 ac
tiv
ity
 (U
/m
g)
⁎⁎⁎
(a)
COMT
훽 Actin
CRS CRS + Li
CO
M
T 
pr
ot
ei
n 
(a
.u
)
0
0.2
0.4
0.6
0.8
0.1
1.2
(b)
Figure 3: Eﬀects of lithium onmonoamine oxidase B (MAO B) enzyme activity (a) and catechol-O-methyltransferase (COMT) protein levels
(b) in the hippocampus of animals exposed to CRS. The values are means ± S E M of 10 rats. Statistical signiﬁcance: ∗∗∗p < 0 001 animals
exposed to CRS+Li vs. CRS animals (t-test). The level of MAO B activity was expressed as units per milligram of protein (U/mg) and
protein levels of COMT were expressed in arbitrary units normalized in relation to β-actin.
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Figure 4: Eﬀects of lithium on the concentration of
malondialdehyde (MDA) in the hippocampus of animals exposed
to CRS. The values are means ± S E M of 10 rats. Statistical
signiﬁcance: ∗∗p < 0 01 animals exposed to CRS+Li vs. CRS
animals (t-test). The ﬁnal result for concentration of MDA was
expressed as μM/mg protein.
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hippocampal BDNF protein, the key neurotrophic factor
involved in the regulation of the release of neurotransmitters.
This adaptive response is probably necessary to maintain the
hippocampal BDNF capacity in conditions provoked by CRS
because the hippocampus is the region that plays a crucial
role in learning andmemory and it is an area also particularly
susceptible to chronic stress [8, 9]. However, lithium treat-
ment decreased high protein levels of BDNF in chronically
stressed rats to the level of unstressed animals. Our results
show that it is possible that lithium has an eﬀect on normal-
izing neuroplasticity in chronically stressed rats. In addition,
in our earlier studies, we found that CRS induced a signiﬁcant
decrease of hippocampal DA concentration [6]. Literature
data have conﬁrmed that the decreased concentration of
DA was observed in many psychiatric and neurodegenerative
disorders, for example, depressive illness and Parkinson’s
disease [19, 38]. It is known that an increase of mono-
amine neurotransmitter levels is an important therapeutic
strategy for several neuropsychiatric disorders [39]. In
the present study, we found that lithium treatment
increased both protein levels of hippocampal TH and con-
centration of DA in chronically stressed rats to the levels
found in unstressed animals [6, 7], which indicates that
lithium enabled de novo synthesis of hippocampal DA in
chronically stressed rats. Lithium may have induced the
gene expression of hippocampal TH in stress condition
through the activator protein-1 (AP-1) transcription factor
pathway [40]. The dynamics of DA transmission is regu-
lated by reuptake through DAT. Dopamine transporter
(DAT) is localized in the plasma membrane of axon termi-
nals, and it reuptakes DA from the synapse [41] and controls
the levels of DA in the extracellular space [42–44]. In this
study, we found that CRS signiﬁcantly increased protein
levels of DAT. The higher protein levels of DAT suggest
that DAT can be upregulated in response to a heightened
demand for uptake of DA in conditions provoked by CRS.
Stress-induced changes in the degradation of nonvesicular
DA may play a role in the decrease of DA transmission.
This is in line with the monoamine hypothesis of depres-
sion which states that depressive disorder is caused by
insuﬃcient signaling by monoamines [45]. An important
result of this study is that lithium treatment in animals
exposed to CRS decreased high protein levels of hippo-
campal DAT to the level of unstressed animals. It is pos-
sible that lithium has an eﬀect on normalizing DA
transmission in chronically stressed rats. In addition, mon-
itoring of DA degradation is important for understanding
dopaminergic turnover. The metabolism of monoamines
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Figure 5: Eﬀects of lithium on enzyme activity from CuZn superoxide dismutase (SOD1) (a), Mn superoxide dismutase (SOD2) (b), catalase
(CAT) (c), glutathione peroxidase (GPx) (d), and glutathione reductase (GR) (e) in the hippocampus of animals exposed to CRS. The values
are means ± S E M of 10 rats. Statistical signiﬁcance: ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001 animals exposed to CRS+Li vs. CRS animals
(t-test). The ﬁnal result for enzyme activity was expressed as units per milligram of protein (U/mg).
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by MAO is the major source of hydrogen peroxide in the
brain [46]. In our previous studies, we found that CRS
induced signiﬁcant increase of enzyme activity of MAO
B, as well as levels of COMT protein in the hippocampus
[7]. These ﬁndings suggest the possibility of increased deg-
radation of monoamine in the hippocampus in chronically
stressed rats [7]. Mallajosyula et al. [47] have shown that
increased MAO B activity in the astrocytes causes Parkinso-
nian. It is known that the inhibition of MAO activity can pro-
long the time during which neurotransmitters are available in
the synaptic cleft [48]. Therefore, the inhibition of MAO
and/or increase of monoamine neurotransmitter levels are
important therapeutic strategies for several neuropsychiatric
disorders [39]. The literature data conﬁrm that lithium is a
very weak inhibitor of MAO. In the present study, we found
that lithium treatment in animals exposed to CRS decreased
hippocampal MAO B activity to the level of unstressed
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Figure 6: Eﬀects of lithium onmRNA and protein levels fromCuZn superoxide dismutase (SOD1) (a), Mn superoxide dismutase (SOD2) (b),
catalase (CAT) (c), glutathione peroxidase (GPx) (d) and glutathione reductase (GR) (e) in the hippocampus of animals exposed to CRS. The
values are means± S.E.M. of 10 rats. Statistical signiﬁcance: ∗p < 0 05 animals exposed to CRS+ Li vs. CRS animals (t-test). The ﬁnal result
was expressed as fold change relative to the calibrator and normalized to cyclophilin A and protein levels was expressed in arbitrary units
normalized in relation to β-actin.
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Figure 7: Eﬀects of lithium on the anxiety index (AI) in animals
exposed to CRS. The values are means± S.E.M. of 10 rats.
Statistical signiﬁcance: ∗∗∗p < 0 001 animals exposed to CRS + Li
vs. CRS animals (t-test).
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animals, while levels of COMT protein remained unchanged.
Decreased enzyme activity of MAO B suggests the possibility
of decreased degradation of DA, which is conﬁrmed by sig-
niﬁcantly increased concentration of DA in the hippocampus
of chronically stressed rats. Our results are in accordance
with the reports of Cesura and Pletscher [39] and Knoll
[49] who found that the increase in DA levels was caused
by MAO B inhibitors. Reduced enzymatic activity of MAO
could contribute to slowing, halting, and possible reversing
of neurodegeneration in dopaminergic neurons which was
initiated by oxidative stress [50]. In pathological conditions,
lithium treatment signiﬁcantly reduces the levels of plasma
lipid peroxides and improves antioxidant status [51, 52].
Decreased hippocampal MDA concentration in chronically
stressed rats treated with lithium, found in this study, con-
ﬁrms that lithium is involved in the reduction of oxidative
stress in chronic stress conditions. Based on our results, it
could be speculated that decreased DA degradation via
MAO may be the way by which lithium reduces oxidative
stress in stress conditions. These ﬁndings suggest that further
investigation of metabolites incurred from oxidative deami-
nation of DA is needed to highlight the exact reason for
reduced oxidative stress.
Modulated activities of antioxidative enzymes SOD,
CAT, and GPx could be markers of oxidative stress. For
example, a level of SOD is decreased when stress conditions
are reduced [53]. The literature data conﬁrm that treatment
with lithium increased mRNA expression of nuclear factor
(erythroid-derived 2)-like 2 (Nrf2), a signaling molecule
which plays an intermediary role in defending against oxida-
tive stress, by orchestrating the gene transcriptions of antiox-
idant enzymes [54–57]. In addition, nuclear factor κB
(NF-κB) is regulated by redox sensitive factors. The absence
of Nrf2 is associated with increased oxidative stress, leading
to the ampliﬁcation of cytokine production, as NF-κB is more
readily activated in oxidative environments [58]. The imbal-
ance between Nrf2 and NF-κB pathways is associated with a
signiﬁcant number of diseases including neurodegeneration
[59]. In the present study, we observed that lithium treat-
ment did not change the gene expression of SOD1, CAT,
GPx, and GR but it decreased the gene expression of
SOD2 in the hippocampus of chronically stressed rats. It
is possible that the treatment with lithium is involved in
maintaining a constant level of the gene expression of
SOD1, CAT, GPx, and GR in chronically stressed rats for
regulating the redox balance and responses to chronic
stress. Furthermore, we recorded that the animals exposed
to CRS treated with lithium showed a decrease of the
enzyme activities of SOD1 and SOD2, while CAT activity
remained unchanged. Our results are consistent with the
reports of Khairova et al. [53] who also found a decrease
in SOD levels, as well as unchanged CAT levels after lith-
ium treatment. It is known that elevated SOD/CAT ratio
suggests an increase in oxidative stress levels, mostly associ-
ated with the elevation in cell hydrogen peroxide concentra-
tion [60]. We recorded a reduction in SOD1/CAT ratio and
SOD2/CAT ratio in animals exposed to CRS after lithium
treatment, compared with CRS animals. This ﬁnding con-
ﬁrms that the reduction in SOD/CAT ratio may indicate
lower oxidative stress, which is reﬂected mainly in a decrease
in the concentration of cell hydrogen peroxide [60].
It is known that treatment with lithium inhibits reactive
oxygen metabolite H2O2-induced cell death in primary cul-
tured rat cerebral cortical cells, suggesting that lithium pro-
duces a protective eﬀect against oxidative stress-induced
cell death [61]. Glutathione (GSH) plays an important role
in the cellular defense against ROS-induced oxidative dam-
age in the brain [61]. Cui et al. [61] found that chronic treat-
ment with lithium increased levels of GSH. The increased
activity of GPx found in our study indicates the increased
reduction of lipid hydroperoxides to their corresponding
alcohols and free hydrogen peroxide to water in chronically
stressed rats treated with lithium. It is possible that the
increased activity of GPx compensated the decreased antiox-
idant capacity of CAT [62] in chronically stressed animals
treated with lithium. Oxidized GSH can be reduced back by
GR. In the present study, we found that treatment with lith-
ium in animals exposed to CRS signiﬁcantly increased the
enzymatic activities of GR. Signiﬁcantly increased enzymatic
activities of hippocampal GR indicate increased reduction of
GSH. It is known that the ratio of reduced GSH to oxidized
GSH within cells is often used as a measure of cellular
oxidative stress. Increased GPx and GR activities may also
be the way by which lithium is involved in the reduction
of oxidative damage in chronically stressed rats treated
with this drug.
In addition, chronic treatment with mood stabilizing
drug lithium in the animals exposed to CRS signiﬁcantly
increased time spent in open arms. This ﬁnding conﬁrms
that lithium stabilizes behavior in animals with anxiety-like
behavior.
In summary, the modulation of hippocampal antioxidant
status and reduced oxidative stress by lithium stabilized
behavior in animals with high anxiety index. In addition,
reduced oxidative stress was followed by the changes of
both dopaminergic turnover and levels of BDNF protein
in chronically stressed rats treated with lithium. These
ﬁndings may be very important in the research on the
eﬀects of lithium on the modulation of antioxidant defense
system in stress-induced diseases.
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